-
Dacarbazine In Vitro: Workflow & Troubleshooting
2026-09-25
Use Dacarbazine to probe DNA-damage responses while separating growth inhibition from actual cell killing. This workflow pairs fresh-solution handling and time-resolved viability measurements with an orthogonal death readout for more interpretable cancer-model comparisons.
-
HNF4A-AS1 Links Lipid Reprogramming to Sorafenib Resistance
2026-09-25
A 2024 study connects reduced HNF4A-AS1 to sorafenib resistance in hepatocellular carcinoma through METTL3- and YTHDF3-linked regulation of DECR1 mRNA, lower PUFA abundance, and reduced ferroptosis sensitivity. Its combination of molecular assays, lipidomics, organoids, and xenografts supports a mechanistic model, while leaving clinical validation and the relevance of other metabolic readouts as open questions.
-
Toremifene vs Tamoxifen in Advanced Breast Cancer
2026-09-24
This Cochrane review synthesized randomized comparisons of toremifene and tamoxifen for advanced breast cancer. It found no clear evidence that either selective estrogen receptor modulator was superior for tumor response, time to progression, overall survival, or the reported adverse effects, while emphasizing that a lack of detected difference is not proof of equivalence.
-
IL-7, Human Recombinant: Biology and Evidence Limits
2026-09-24
IL-7, human recombinant (P1024), is a cataloged recombinant cytokine, but the available product information does not establish its formulation, potency, or experimental dose. This article separates established IL-7 receptor biology from a cited SARS-CoV-2 protease study, which does not test IL-7 or P1024.
-
Ziprasidone Targets GOT1 in Pancreatic Cancer
2026-09-23
The reference study identifies ziprasidone as a noncompetitive GOT1 inhibitor that disrupts glutamine metabolism, redox balance, and proliferation in pancreatic ductal adenocarcinoma models. Its combination of biochemical, metabolomic, cellular, genetic, and xenograft evidence supports GOT1 as a mechanistically grounded target, while leaving questions about selectivity, pharmacology, and clinical translation.
-
AI-10-49 and the Next Wave of inv(16) AML Research
2026-09-23
AI-10-49 offers a mechanism-led way to study CBFβ-SMMHC-driven leukemia, connecting fusion-protein disruption with RUNX1 reactivation, MYCN suppression, and the N-MYC/eIF4G1 survival program. This translational perspective outlines how researchers can move beyond viability screening toward target engagement, chromatin biology, and disease-relevant validation.
-
From Nurr1 Gradients to Aqueous Click Labeling
2026-09-22
A translational framework for connecting claustrum neurogenesis, Nurr1 mapping, and Sulfo-Cy3 azide-enabled bioconjugation in aqueous biological samples.
-
TAK-715 for Reproducible p38 MAPK Assays
2026-09-21
This scenario-based guide explains how TAK-715 (SKU A8688) can support interpretable cell viability, proliferation, and cytokine-signaling experiments through controlled formulation, dosing, and mechanistic validation. It distinguishes biochemical potency from cellular response and provides practical criteria for selecting a reliable p38 MAPK inhibitor.
-
BIRB 796: Interpreting p38α Signaling
2026-09-21
BIRB 796 (Doramapimod) is a highly selective p38α MAPK inhibitor with an unusual allosteric mechanism. This guide explains how its effects on kinase activity, dephosphorylation, cytokine signaling, and apoptosis should be interpreted in advanced research assays.
-
Building a Translational Map for Vascular Assays
2026-09-20
A mechanistic and strategic framework for translating VEGF/Ang/Tie2 biology into rigorous retinal angiogenesis studies, while positioning 4-Methoxychalcone-1 as an exploratory small-molecule research reagent rather than an unvalidated therapeutic claim.
-
Whole-Blood Stimulation Reveals Metabolic Control
2026-09-19
Zhao and colleagues present a standardized ex vivo whole-blood protocol that links defined immune stimulation with targeted metabolic intervention and cytokine measurement. The approach preserves cellular and plasma context while improving comparability across donors, making it useful for immunometabolism, fatty acid oxidation pathway research, and translational assay development.
-
FAK Inhibitor 14: A Causal Assay Framework
2026-09-19
FAK Inhibitor 14 enables controlled interrogation of adhesion, migration, and EMT-linked signaling. This guide translates chronic cholesterol-stress findings into a rigorous assay strategy for cancer biology research and tumor metastasis research.
-
Mubritinib (TAK 165): Assay Design Guide
2026-09-18
This scenario-based guide explains how to select concentrations, manage solubility, interpret viability data, and compare vendors when using Mubritinib (TAK 165), SKU B1543. It connects complex I inhibition with practical AML, PEL, HER2, and assay-validation workflows while distinguishing product-supported evidence from laboratory recommendations.
-
Reactive Oxygen Species Assay Kit for FLASH-RT
2026-09-18
Use live-cell DCFH-DA fluorescence to connect treatment exposure with oxidative stress, apoptosis, and DNA-damage phenotypes. This workflow translates the BRD4-targeted FLASH-radiotherapy findings into practical controls, timing experiments, and troubleshooting decisions without treating ROS fluorescence as a standalone mechanism.
-
SP600125 JNK Inhibitor: Applied Workflows
2026-09-17
SP600125 offers a practical way to test JNK-dependent phosphorylation, cytokine release, and cell-death phenotypes across cellular and inflammatory models. This guide combines compound-handling guidance with assay controls and a phosphosite-aware strategy inspired by recent chemoproteomic research.